Triantafyllidou Olga, Sigalos Giorgos, Gkoles Laertis, Kastora Stavroula, Vakas Panagiotis, Batsiou Eugenia, Vlahos Nikos
Reproductive Medicine Unit, "Leto" Maternity Hospital, Mouson Str. 7-13, Athens, 11524, Greece.
Reproductive Medicine Unit, "Leto" Maternity Hospital, Mouson Str. 7-13, Athens, 11524, Greece.
Eur J Obstet Gynecol Reprod Biol. 2020 Aug;251:136-140. doi: 10.1016/j.ejogrb.2020.05.026. Epub 2020 Jun 5.
Poor ovarian response (POR) is one of the most challenging problems in assisted reproduction. Several strategies have been used to improve pregnancy rates. The use of Clomiphene Citrate (CC) has been shown to improve ovarian stimulation outcomes and decrease gonadotropin requirements in women of advanced reproductive age. However, the combination of CC and gonadotropins to improve pregnancy rates after in IVF in poor responders is still unexplored due to the small number of trials with few participants. This is a prospective cohort trial involving 12 patients diagnosed with poor ovarian response who underwent ovarian stimulation during the period between June 2015 and September of 2017. All patients were treated with the maximum dose of gonadotropins (hMG, 300 IU/day, hMG group) according to a short gonadotropin/GnRH antagonist protocol. In a subsequent cycle those patients underwent the same stimulation protocol with the addition of 100 mg of CC from day 3 to day 7 (CC-hMG group). Supplementation with 100 mg of CC resulted in a statistically significant increase in estradiol levels, number of follicles and number of oocytes retrieved, as well as an increase in the number of total embryos available for transfer. Furthermore, a significant reduction was observed in cancellation rates in the CC-hMG group. Two clinical pregnancies, which resulted in two live births and 3 biochemical pregnancies were achieved in the CC/hMG group. Furthermore, by employing open-source, biological data we identified a common gene (Estrogen Receptor 1, ESR1) between genetic targets of clomiphene treatment and POR which could explain the benefits of clomiphene in this group of patients. In conclusion, the addition of CC 100 mg to the stimulation regimen in women diagnosed with POR and previous failed IVF cycles could improve stimulation results, but this study could not demonstrate any benefit in terms of clinical pregnancies and live births. The effectiveness of this treatment requires further investigation.
卵巢低反应(POR)是辅助生殖中最具挑战性的问题之一。已经采用了多种策略来提高妊娠率。已证明使用枸橼酸氯米芬(CC)可改善高龄育龄女性的卵巢刺激效果并减少促性腺激素用量。然而,由于参与试验的人数较少,CC与促性腺激素联合使用以提高IVF后低反应者的妊娠率这一情况仍未得到充分研究。这是一项前瞻性队列试验,纳入了12例被诊断为卵巢低反应的患者,这些患者在2015年6月至2017年9月期间接受了卵巢刺激。所有患者均根据短方案促性腺激素/ GnRH拮抗剂方案接受最大剂量的促性腺激素治疗(hMG,300IU/天,hMG组)。在随后的周期中,这些患者接受相同的刺激方案,并从第3天至第7天添加100mg CC(CC-hMG组)。补充100mg CC导致雌二醇水平、卵泡数量、获取的卵母细胞数量在统计学上显著增加,以及可用于移植的总胚胎数量增加。此外,CC-hMG组的取消率显著降低。CC/hMG组实现了2例临床妊娠,产下2例活产婴儿,还有3例生化妊娠。此外,通过使用开源生物数据,我们在氯米芬治疗的基因靶点和POR之间鉴定出一个共同基因(雌激素受体1,ESR1),这可以解释氯米芬对该组患者的益处。总之,对于诊断为POR且先前IVF周期失败的女性,在刺激方案中添加100mg CC可改善刺激结果,但本研究未能证明在临床妊娠和活产方面有任何益处。这种治疗方法的有效性需要进一步研究。